Patent-Blocking Strategies May Stunt Research
This article was originally published in Scrip
The patent-blocking strategies being used by some international advocacy groups to promote access to cheaper drugs in developing nations can be seen to be good thing; however, it is important that issues concerning the availability of the drug and the pricing of the drug are kept separate. If there is pressure on patent courts to decide against awarding a patent to a drug company because there is a desire to have the drug at a low price, this results in a conflict of interests and will fundamentally invalidate the patent system. If such situations occur they could stunt vital drug research programs, writes patent attorney Adrian Tombling.
Register for our free email digests: